NeuroTherapia, Inc. is advancing NTRX-07, an investigational orally administered CB2 agonist, through a Phase 1 clinical trial targeting early Alzheimer's Disease (AD) and mild cognitive impairment (MCI). The Alzheimer's therapeutics market is projected to grow significantly, driven by the increasing prevalence of the disease and the demand for effective treatments. NTRX-07's unique mechanism of action may position it favorably against existing therapies, particularly in a landscape where disease-modifying treatments are scarce. The completion of this trial could enhance NeuroTherapia's portfolio and attract potential partnerships or acquisitions, especially if safety and pharmacokinetic profiles are favorable.